Overview
Bloomlife provides a remote prenatal care platform for healthcare providers using the FDA-cleared MFM-Pro wearable patch to non-invasively monitor maternal and fetal heart rates outside the clinic. Clinicians prescribe the patch; patients wear it; data is collected and interpreted by clinical teams and fed into EMR systems, while Bloomlife handles logistics and the service is reimbursed through insurers. It differentiates itself by targeting high-risk pregnancies with a clinically focused, prescription-based B2B2C model that integrates with EMRs and third-party devices, rather than selling directly to consumers. Its goal is to make prenatal care safer and more accessible by reducing in-clinic visits and manual monitoring while improving maternal and fetal health management.
Work here?Claim your company
Simplify's Take
What believers are saying
- Bloomlife raised $12.2 million in 2024, funding commercial expansion and a second device.
- Valley Perinatal Services partnership launched January 2026, validating high-risk hypertension monitoring demand.
- Open 2026 hiring for commercial operations and software signals active scaling, not retrenchment.
What critics are saying
- Reimbursement dependence ties revenue to fragile remote-monitoring billing rules and provider coding.
- MFM-Pro commercialization still needs adoption beyond pilot sites like Valley Perinatal Services.
- Bloomlife's narrow maternal-care niche faces existential pressure if payers reject home fetal monitoring.
What makes Bloomlife unique
- FDA-cleared MFM-Pro monitors maternal and fetal heart rates at home.
- Bloomlife integrates remote monitoring with EMR workflows for high-risk prenatal care.
- PeriGen partnership adds AI-driven fetal surveillance inside existing hospital workflows.
Help us improve and share your feedback! Did you find this helpful?